Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)

Sponsor

PDL BioPharma, Inc.